<DOC>
	<DOCNO>NCT02007655</DOCNO>
	<brief_summary>The primary objective study : - To estimate incidence rate unexpected adverse event - To characterize bleed event assess risk factor bleed - To identify ancillary baseline variable may also associate adverse outcome</brief_summary>
	<brief_title>Eliquis Safety Surveillance Japanese Patients With NonValvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Patients begin receive treatment product approve indication , dosage , administration include study Patients receive Eliquis outside approve indication exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cardiovascular</keyword>
</DOC>